Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

66 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Quality of Life in Older Adults After Major Cancer Surgery: The GOSAFE International Study.
Montroni I, Ugolini G, Saur NM, Rostoft S, Spinelli A, Van Leeuwen BL, De Liguori Carino N, Ghignone F, Jaklitsch MT, Somasundar P, Garutti A, Zingaretti C, Foca F, Vertogen B, Nanni O, Wexner SD, Audisio RA; SIOG Surgical Task Force/ESSO GOSAFE Study Group. Montroni I, et al. Among authors: zingaretti c. J Natl Cancer Inst. 2022 Jul 11;114(7):969-978. doi: 10.1093/jnci/djac071. J Natl Cancer Inst. 2022. PMID: 35394037 Free PMC article.
GOSAFE - Geriatric Oncology Surgical Assessment and Functional rEcovery after Surgery: early analysis on 977 patients.
Montroni I, Rostoft S, Spinelli A, Van Leeuwen BL, Ercolani G, Saur NM, Jaklitsch MT, Somasundar PS, de Liguori Carino N, Ghignone F, Foca F, Zingaretti C, Audisio RA, Ugolini G; SIOG surgical task force/ESSO GOSAFE study group. Montroni I, et al. Among authors: zingaretti c. J Geriatr Oncol. 2020 Mar;11(2):244-255. doi: 10.1016/j.jgo.2019.06.017. Epub 2019 Sep 3. J Geriatr Oncol. 2020. PMID: 31492572
How Many Cancer Clinical Trials Can a Clinical Research Coordinator Manage? The Clinical Research Coordinator Workload Assessment Tool.
Fabbri F, Gentili G, Serra P, Vertogen B, Andreis D, Dall'Agata M, Fabbri G, Gallà V, Massa I, Montanari E, Monti M, Pagan F, Piancastelli A, Ragazzini A, Rudnas B, Testoni S, Valmorri L, Zingaretti C, Zumaglini F, Nanni O. Fabbri F, et al. Among authors: zingaretti c. JCO Oncol Pract. 2021 Jan;17(1):e68-e76. doi: 10.1200/JOP.19.00386. Epub 2020 Sep 16. JCO Oncol Pract. 2021. PMID: 32936710
Hydroxychloroquine as Prophylaxis for COVID-19: A Review.
Monti M, Vertogen B, Masini C, Donati C, Lilli C, Zingaretti C, Musuraca G, De Giorgi U, Cerchione C, Farolfi A, Cortesi P, Viale P, Martinelli G, Nanni O. Monti M, et al. Among authors: zingaretti c. Front Pharmacol. 2020 Dec 3;11:605185. doi: 10.3389/fphar.2020.605185. eCollection 2020. Front Pharmacol. 2020. PMID: 33343376 Free PMC article. Review.
PROTECT Trial: A cluster-randomized study with hydroxychloroquine versus observational support for prevention or early-phase treatment of Coronavirus disease (COVID-19): A structured summary of a study protocol for a randomized controlled trial.
Nanni O, Viale P, Vertogen B, Lilli C, Zingaretti C, Donati C, Masini C, Monti M, Serra P, Vespignani R, Grossi V, Biggeri A, Scarpi E, Galardi F, Bertoni L, Colamartini A, Falcini F, Altini M, Massa I, Gaggeri R, Martinelli G. Nanni O, et al. Among authors: zingaretti c. Trials. 2020 Jul 31;21(1):689. doi: 10.1186/s13063-020-04527-4. Trials. 2020. PMID: 32736597 Free PMC article.
Is it possible to conduct clinical trials during a pandemic? The example of a trial of hydroxychloroquine.
Lilli C, Biggeri A, Zingaretti C, Vertogen B, Frassineti V, Vespignani R, Grossi V, Florescu C, Matteucci L, Pazzi C, Bongiovanni A, Limarzi F, Fausti V, Bertoni L, Donati C, Galardi F, Gentili N, Mazza F, Martinelli G, Nanni O. Lilli C, et al. Among authors: zingaretti c. Epidemiol Prev. 2021 Jan-Apr;45(1-2):28-36. doi: 10.19191/EP21.1-2.P028.036. Epidemiol Prev. 2021. PMID: 33884840 Free article. Clinical Trial. English.
Promoter methylation of tumor suppressor genes in pre-neoplastic lesions; potential marker of disease recurrence.
Rengucci C, De Maio G, Casadei Gardini A, Zucca M, Scarpi E, Zingaretti C, Foschi G, Tumedei MM, Molinari C, Saragoni L, Puccetti M, Amadori D, Zoli W, Calistri D. Rengucci C, et al. Among authors: zingaretti c. J Exp Clin Cancer Res. 2014 Aug 5;33(1):65. doi: 10.1186/s13046-014-0065-x. J Exp Clin Cancer Res. 2014. PMID: 25091577 Free PMC article.
66 results